Kennondale Capital Management LLC Has $571,000 Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)

Kennondale Capital Management LLC decreased its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 50.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 14,108 shares of the company's stock after selling 14,109 shares during the period. Kennondale Capital Management LLC's holdings in Akero Therapeutics were worth $571,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in AKRO. RTW Investments LP increased its position in shares of Akero Therapeutics by 15.9% in the 4th quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock valued at $190,840,000 after buying an additional 940,388 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Akero Therapeutics by 13.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,321,972 shares of the company's stock valued at $120,238,000 after buying an additional 513,613 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Akero Therapeutics by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 3,704,411 shares of the company's stock valued at $103,057,000 after buying an additional 27,830 shares in the last quarter. Deep Track Capital LP increased its position in shares of Akero Therapeutics by 116.0% in the 4th quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock valued at $41,452,000 after buying an additional 800,216 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Akero Therapeutics by 93.3% in the 1st quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company's stock valued at $46,786,000 after buying an additional 557,794 shares in the last quarter.

Analyst Ratings Changes

A number of research firms recently commented on AKRO. Citigroup lowered their price objective on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Bank of America increased their target price on Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a report on Tuesday, May 27th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $82.50.

Insider Activity

In other Akero Therapeutics news, CTO Scott A. Gangloff sold 848 shares of the firm's stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $54.84, for a total transaction of $46,504.32. Following the completion of the sale, the chief technology officer directly owned 23,452 shares in the company, valued at $1,286,107.68. This trade represents a 3.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Timothy Rolph sold 12,500 shares of Akero Therapeutics stock in a transaction that occurred on Monday, July 7th. The shares were sold at an average price of $51.09, for a total transaction of $638,625.00. Following the completion of the sale, the insider owned 167,124 shares of the company's stock, valued at approximately $8,538,365.16. The trade was a 6.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 242,156 shares of company stock valued at $12,119,228. Company insiders own 7.07% of the company's stock.

Akero Therapeutics Stock Down 0.2%

Shares of NASDAQ AKRO traded down $0.08 during mid-day trading on Tuesday, hitting $51.30. The company had a trading volume of 38,403 shares, compared to its average volume of 1,458,354. The company has a market capitalization of $4.09 billion, a PE ratio of -26.28 and a beta of -0.15. The firm has a 50-day simple moving average of $50.63 and a two-hundred day simple moving average of $44.58. The company has a current ratio of 16.80, a quick ratio of 16.80 and a debt-to-equity ratio of 0.03. Akero Therapeutics, Inc. has a one year low of $21.34 and a one year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $1.91. On average, equities analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.

Want to see what other hedge funds are holding AKRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.